Checklist for Tysabri (natalizumab) Referral

Required documentation for all initial referrals

			neganea	documentation	or an initial rejerrals	,				
Patient	· 			DOB	Date	New Start Maintenance				
Please	return	completed c	necklist and ched	cklist items for an	infusion referral:					
	Patient demographics (e.g. address, phone number, SSN, etc.)									
	Insurance information and copy of insurance card(s). Please indicate the insurance that is primary, and the insurance that is secondary, if applicable, and the subscriber's date of birth.									
	o	If insurance	requires prior au		provide the phone no	umber and allow up to 15-30 days				
	Signed and completed Tysabri Standard Order (our order form) with ICD diagnosis code o Standard Order forms are available at lowcountryrheumatology.com/infusions/ New order required every 6 months per PI									
	Compl	eted and sign	ed Tysabri Start F	orm						
	Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy, and how long patient has been on Tysabri.									
	Required TB screening results: PPD or QuantiFERON Gold Test (within 3 years) Date:									
	Required Hepatitis screening (within 1 year) : Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, and Hepatitis B Core Antibody results.									
	Required JCV results									
	Required baseline MRI									
	New Starts: Herpes zoster vaccination status? (Please check one) Yes No									
	In women of child-bearing age, ensure birth control									
 Please indicate name and direct phone number of a contact within your office that we can speak any additional information: Name: 										
	0	Phone Num	ber:							
			Paperwork	can be faxed or em	nailed to (843)-793-61	81				
			Infusion Coord	inators can assist	you with any questi	ions at				
				(843)-572-	8932					
		Low Country Rheumatology Infusion Locations Please mark preferred location and we will do our best to accommodate, however we cannot make any guarantees.								
	Please r	mark preferred	location and we w	rill do our best to acc	ommodate, however we	e cannot make any guarantees.				
				Summery						
			2001 2n/	4 AVA SINTA 201 Ci	immorvilla SC 20186					

2001 2nd Ave, Suite 201, Summerville, SC 29486

Mount Pleasant

1100 Johnnie Dodds Blvd, Mt Pleasant, SC 29464

West Ashley

2291 Henry Tecklenburg Drive, Charleston, SC 29414

Low Country Rheumatology Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our Infusion Coordinators will notify you if any further info Ve will rev nk you for

ormation is required. The patient will have an annual 30-minute consult with our NP to obtain H&P for c iew financial responsibility with the patient and refer them to any available co-pay assistance as required the referral!							
Low Country Rheumatology Use Only	Existing Patient Yes	No	Physician				

Standard Orders for Tysabri (natalizumab) Administration

Patient	DOB	Date	2								
*NOTE: Patient may be ineligible to receive											
		-	_								
infectious process, antifungal therapy, or active fever due to the possibility of developing a super infection related to its effect on the immune system. Patient is ineligible to receive Tysabri if they have new-onset or deteriorating neurological changes and/or upcoming surgery. Orders must be renewed every 6 months per Pl.											
☐ G35 Relapsing Multiple Sclerosis	☐ K50.00 Moderate to Sever	to Severe Active									
USS Relapsing Wartiple Scienosis	Crohn's	Severe Active									
	Croim's										
History:											
Baseline MRI date:	1.3										
Last JCV date: (Please attach result)											
□ HBsAg, HBsAb, HB core Ab results											
□ Reauthorization/status report every month. Date:											
$\ \square$ Any other immunosuppression drugs:											
$\hfill\Box$ Recent or upcoming surgical procedure: $\hfill\Box$	Yes □ No										
Orders:											
□ Standard Order Protocol:											
Obtain patient weight each visit											
· · · · · · · · · · · · · · · · · · ·		-	the 1-hour post infusion observation								
period, and prior to discharge home	•	more frequently	if patient's condition warrants it.								
Maintain IV access during observation	-	. (1)									
Administer Tysabri IV as directed po		out a filter.									
Assess patient for response to there		6									
 If infusion reaction occurs, slow or and Procedure Manual. 	stop infusion, and initiate inf	rusion reaction p	protocol per Articularis Healthcare Policy								
 Instruct patient/caregiver on medic 	entions signs/symptoms of ad	warsa raastian									
·			number with instructions to call that								
number for infusion reaction after of											
Dose:	alsonarge and renew up appear	memeric seriedaie									
Standard Dose Protocol: Tysabri (natalizuma	ab) 300 mg over 1-hour Q 4 we	eeks									
,	, ,										
Premedicate:											
Pre-medicate x 1 dose 30 minutes prior to e	ach infusion with:										
□ Acetaminophen											
□ 500 mg PO □ 1000 n	ng PO										
□ Diphenhydramine	55 35 115 50										
□ 25 mg PO □ 50 mg	PO □ 25 mg IVP □ 50	mg IVP									
□ Solu-Medrol	a IVD — Other										
□ 62.5 mg IVP □ 100 mg	-										
·	☐ 4 mg IVP Ondansetron ☐ 1	10 mg PO Loratac	dine								
□ 10 mg PO Cetirizine		150 mg PO Raniti									
10 mg r o cetinzine	10 mg r o cettrizine	130 mg i O namu	diffe								
Additional orders/comments:											
•											
											
Practice Name:		NIDI:									
	,	INF I.									
Physician Name:		State License: _									
Physician Signature:											
i iiysiciaii sigilatule		DEA #:									
Date:		UPIN:									